Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2922 - Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Psychosocial Aspects of Cancer;  Immunotherapy;  Supportive and Palliative Care;  Melanoma


Annelies Boekhout


Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377


A.H. Boekhout1, M. Hauptmann2, A.J.M. van den Eertwegh3, G.A.P. Hospers4, J.W.B. de Groot5, M.J.B. Aarts6, E. Kapiteijn7, A.J. Ten Tije8, D. Piersma9, W.H.J. Kruit10, K.P.M. Suijkerbuijk11, F.W.P.J. Berkmortel12, G. Vreugdenhil13, R.H. Koornstra14, E. Fiets15, M. Lees16, K.J.M. Janssen17, L.V. van den Poll-Franse18, C.U. Blank19

Author affiliations

  • 1 Psychosocial Research And Epidemiology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 2 Epidemiology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 3 Medical Oncology, VU University Medical Centre, Amsterdam/NL
  • 4 Medical Oncology, University Medical Centre Groningen, Groningen/NL
  • 5 Medical Oncology, Isala, Zwolle/NL
  • 6 Medical Oncology, Maastricht University Medical Centre, Maastricht/NL
  • 7 Medical Oncology, Leiden University Medical Centre, Leiden/NL
  • 8 Medical Oncology, Amphia hospital, Breda/NL
  • 9 Medical Oncology, Medical Spectrum Twente, Enschede/NL
  • 10 Medical Oncology, Erasmus University Medical Centre, Rotterdam/NL
  • 11 Medical Oncology, University Medical Centre Utrecht, Utrecht/NL
  • 12 Medical Oncology, Atrium Medical Centre, Sittard/NL
  • 13 Medical Oncology, Maxima Medical Centre, Eindhoven/NL
  • 14 Medical Oncology, Radboud Medical Centre, - - Nijmegen/NL
  • 15 Medical Oncology, Medical Centre Leeuwarden, Leeuwarden/NL
  • 16 Oncology, Bristol-Meyers Squibb, Paris/FR
  • 17 Oncology, Bristol-Meyers Squibb, Utrecht/NL
  • 18 Psychosocial Research And Epidemiology, Netherlands Cancer Institute, Amsterdam/NL
  • 19 Medical Oncology, Netherlands Cancer Institute, Amsterdam/NL


Abstract 2922


After the introduction of ipilimumab, an anti-CTLA-4 monoclonal antibody, durable, long term survival has become a possibility for a subgroup of advanced melanoma patients. Since ipilimumab is a relatively novel drug there are limited data on the long-term physical, psychological, and social functioning of these patients. This study will evaluate the long-term physical and psychosocial performances and the information needs of advanced melanoma survivors who have been treated with ipilimumab.

Trial design

This is a prospectively enrolling, multicentre cohort study. Objectives: To assess health-related quality of life (HRQoL), anxiety, depression, fatigue, fear of cancer recurrence, sexual health and generic health status in patients with advanced melanoma who have survived at least 2 years after ipilimumab treatment (without subsequent other systemic therapies) as compared with healthy controls, and to describe the melanoma-specific HRQoL, impact of cancer, social functioning and information needs in patients with advanced melanoma who have survived at least 2 years after ipilimumab treatment. Patients and healthy control population: Patients with advanced (stage IV or unresectable stage III) melanoma who survived at least 2 years and were treated with ipilimumab between 2011 and 2015 in 14 hospitals in the Netherlands are included. The patient population consists of 3 treatment groups based on time since ipilimumab treatment: 24 to 

Clinical trial identification

Date of release: November 2016

Legal entity responsible for the study

Netherlands Cancer Institute


Bristol-Myers Squibb


A.H. Boekhout: Employee of Bristol-Myers Squibb. M. Lee, KJM Janssen: Employee of and receiving stock from Bristol-Myers Squibb, during the conduct of the study. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.